KLRA

Conviction 43HealthcareScan · Thu, Sep 24, 2026

Kailera Therapeutics, Inc. (KLRA) closed at $11.98 (-8.80%) on Sep 24, 2026. Price is below its 50-day. RSI(14) 32, -53.9% from its 52-week high, -53.9% year to date. Sector: Healthcare · Biotechnology.

KLRA$11.98-8.80%

ResistanceSupportVol 14Insider buy

Vol MA14 1.23M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Kailera Therapeutics, Inc.Biotechnologywww.kailera.com ↗

Price11.98

Change-8.80%

Gap-0.04%

Rel volume2.64×

Avg volume1.1M

Avg $ vol15.24M

SMA 2014.50

SMA 5016.53

SMA 200—

Price vs 50-27.57%

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 15.58

RSI (14)32

MACD hist-0.13

MACD cross—

Stoch %K / %D4 / 17

ADX (14)34

+DI / −DI8 / 30

RSI divergence—

MACD divergence—

ATR %9.01%

ADR %7.63%

52w high26.00

52w low11.98

From 52w high-53.94%

Above 52w low+0.00%

New 52w highNo

SqueezeOff

Bollinger width48.55%

%B0.14

Donchian pos2.86%

Donchian high18.78

Donchian low11.78

AVWAP (52w high)19.11

vs AVWAP high-37.33%

AVWAP (52w low)12.29

vs AVWAP low-2.58%

OBV trendDown

Chaikin MF (20)-0.15

Today vs 20d2.64×

Avg vol (14d)1.23M

Avg vol (20d)1.1M

Avg $ vol (20d)15.24M

Market cap1.55B

RS Rating—

RS 3m (vs SPY)-46.53%

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank13.2

1 week-7.31%

1 month-32.54%

3 months-42.04%

6 months—

1 year—

YTD-53.94%

P/E—

P/B1.39

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current11.11

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target45.00

Target upside275.78%

Analyst ratingBuy

Institutional88.24%

Ent. value1.42B

Revenue—

Net income-111.31M

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out129.57M

Employees—

ListedFri, Apr 17, 2026

Free float58.48M

Float %45.1%

Short interest5.66M

Days to cover6.5d

Short volume27.5%

Squeeze score59 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$1.09 vs −$0.74

Last surprise-47.3% miss

Setup gradeD

Conviction43 / 100

Pattern quality—

Tech rank13.2 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance19.15

Support13.50

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in KLRA

All disclosures →

No recent disclosed trades by Congress in KLRA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in KLRA · open-market 2 buys

Insider	Side	Shares	Value	Traded	Filed
Nicholson Nur Chief Technology Officer · Stock Option (right to buy) · 2026-09-07	Grant	220K	—	2026-09-07	2026-09-09
Tregoning Kathleen See Remarks · Stock Option (right to buy) · 2026-07-06	Grant	175K	—	2026-07-06	2026-07-08
Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner · Common Stock · 2026-04-20	Convert	9.48M	—	2026-04-20	2026-04-22
WONG RODERICK 10% owner · Common Stock · 2026-04-20	Buy	500K	$8.0M	2026-04-20	2026-04-22
RTW INVESTMENTS, LP 10% owner · Series B Preferred Stock · 2026-04-20	Convert	2.03M	—	2026-04-20	2026-04-22
RTW INVESTMENTS, LP 10% owner · Series A Preferred Stock · 2026-04-20	Convert	8.25M	—	2026-04-20	2026-04-22
WONG RODERICK 10% owner · Series B Preferred Stock · 2026-04-20	Convert	2.03M	—	2026-04-20	2026-04-22
RTW INVESTMENTS, LP 10% owner · Common Stock · 2026-04-20	Buy	500K	$8.0M	2026-04-20	2026-04-22
Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% owner · Common Stock · 2026-04-20	Other	—	—	2026-04-20	2026-04-22
RTW INVESTMENTS, LP 10% owner · Common Stock · 2026-04-20	Convert	10.28M	—	2026-04-20	2026-04-22

SEC filings

EDGAR filings in KLRA · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.